Dr. Tim Illidge

I

s a Professor and Honorary Consultant Oncologist at University of Manchester. His research as clinician scientist has focused on the development of antibodies as therapeutics in cancer therapy either as antibody drug conjugates, radioimmunoconjugates or in combination with external beam radiotherapy (RT). Dr. Illidge is the Co-leader of ROBIN MCT coordinate internationally. This includes processing and analysis of clinical samples in Manchester.